Topics

Companies Related to "A Phase 1 Study in Healthy Volunteers for AL101" [Most Relevant Company Matches] RSS

06:29 EST 21st January 2020 | BioPortfolio

Here are the most relevant search results for "A Phase 1 Study in Healthy Volunteers for AL101" found in our extensive corporate database of over 50,000 company records.

Showing "Phase Study Healthy Volunteers AL101" Companies 1–25 of 2,300+

Extremely Relevant

Ayala Pharmaceuticals, Inc.

Ayala Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to developing targeted cancer therapies for people living with genetically defined cancers. Ayala is broadly developing its product candidates, AL101 and AL102, best-in-class gamma secretase inhibitors, with clinical and nonclinical studies underway in both solid tumors (AL...


Relevant

Northwest Kinetics Incorporated

Northwest Kinetics is an independent research facility which specializes in Phase I and Phase II clinical pharmaceutical studies. Northwest Kinetics provides a full range of services for both short and long-term Phase I and II trials. Our services can include review of protocol design, pharmacokinetic consultation, patient recruitment, study execution, data management and record keeping, and repor...

Ardea Biosciences, Inc.

Ardea Biosciences, Inc., of San Diego, California, is a biotechnology company focused on the development of small-molecule therapeutics for the treatment of gout, cancer and human immunodeficiency virus (HIV). RDEA594, our lead product candidate for the treatment of hyperuricemia and gout, is a selective URAT1 transporter inhibitor in Phase 2 clinical development. Our next-generation URAT1 inhib...


Vince & Associates Clinical Research

Since its formation in 2001 Vince & Associates Clinical Research has grown to become one of the leading multi-specialty clinical research sites in the US offering Phase I-IV clinical trials. Dr. Vince and his team are well known for their recruitment and retention of research volunteers in clinical trials including disease state populations as well as heal...

Imara, Inc.

Imara, Inc. is dedicated to developing novel therapeutics for patients with sickle cell disease and other hemoglobinopathies. Imara is currently developing IMR-687, a highly selective, potent small molecule inhibitor of PDE9, to treat patients with sickle cell disease. IMR-687 has been specifically designed to treat patients with sickle cell disease by bot...

Pharmacon Research GmbH

Pharmacon Research is an independent contract research organization (CRO) with headquarters in Berlin and clinical sites in Prague, Warsaw, Bratislava and Budapest. Founded in 1992 by the management of a successful Phase I unit, Pharmacon Research focuses on specific Phase I studies in patients and symptomatic subjects and on early Phase II studies (dose finding, proof of concept). Irrespective of...

Ayala Pharmaceuticals

Ayala Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing targeted cancer therapies for people living with genetically defined cancers. The company was founded in November 2017 with an experienced global management team and a strong investor base. The management bench recently expanded with the appointment of Andrea Vergar...

Vivus

VIVUS, Inc. is a pharmaceutical company dedicated to the development and commercialization of next-generation therapeutic products addressing obesity and sexual health. Analysts speculate that the potential market for obesity ranges from $5 billion to $10 billion annually, and the indications targeted by VIVUS' sexual health products each represent a projected market greater than $1 billion annual...

ESCAPE Bio, Inc.

ESCAPE Bio is a clinical stage, privately held biopharmaceutical company developing novel precisely targeted therapeutics for genetically defined neurodegenerative diseases. ESB1609 is in a Phase 1\1b randomized, double-blind, placebo-controlled, safety, tolerability, pharmacokinetic and biomarker study of escalating multiple doses in healthy volunteers and subjects with Niemann-Pick Disease Type...

Clinical Network Services (CNS)

Clinical Network Services (CNS) Pty Ltd is an Australian CRO, focused on providing full contract research organisational clinical trial services to the international healthcare community particularly during the early phase (Phase I and Phase II) clinical development of their products. CNS has established itself as Brisbane’s only headquartered Australian CRO working both nationally with dedicat...

Ameritox

The single-group, multi-dose study examined the ability of the Rx Guardian(SM) algorithm to differentiate among low, medium and high daily doses of OxyContin®. Oxycodone levels were detected in the urine of 36 healthy volunteers using a liquid chromatography-mass spectrometry (LC-MS-MS) assay. Participants were randomized to receive 80mg, 160mg or 240mg of daily OxyContin® to steady state cond...

BioLineRx Ltd. and Compugen Ltd.

BioLineRx Ltd. is a publicly-traded biopharmaceutical development company. It is dedicated to building a portfolio of products for unmet medical needs or with advantages over currently available therapies. BioLineRx’s current portfolio consists of five clinical stage candidates: BL-1020 for schizophrenia has commenced a Phase II/III study; BL-1040 for...

PhaseOneTrials A/S

PhaseOneTrials A/S is the "first in class" independent Danish contract research clinic. We are based at Hvidovre University Hospital in the heart of Medicon Valley, Denmark. On this website you can learn more about us, our competence areas, and how to join our register of healthy volunteers.Our core competence is full service, high quality conduct of phase 1 clinical trials as well as early phase ...

Volunteers of America

Volunteers of America is a national, nonprofit, faith-based organization dedicated to helping those in need live healthy, safe and productive lives. Since 1896, our ministry of service has supported and empowered America's most vulnerable groups, including seniors, people with disabilities, at-risk youth, men and women returning from prison, homeless individuals and families, those recovering from...

AnorMED Inc.

AnorMED was founded in 1996 and listed on the TSX as “AOM” in 1999 and on the AMEX as "AOM" in 2005. To date, the Company has raised over $160 million to support its research and development programs. Over the past years AnorMED has grown to over 140 employees - the majority of which are scientists - including chemists, biochemists and biologists. Unlike many biotech companies that focus on d...

Allegro Ophthalmics, LLC,

Allegro Ophthalmics, LLC is a privately held biopharmaceutical company focused on the development of novel anti-integrin therapies for the treatment of ocular diseases. Allegro’s lead investigational drug risuteganib (Luminate®) successfully completed two Phase 2 diabetic macular edema (DME) studies and is currently being evaluated in a U.S. ...

ProFibrix B.V.

Fibrocaps is based on a mixture of two essential blood clotting proteins, fibrinogen and thrombin, and is a unique dry powder topical tissue sealant in development to stop bleeding after or during surgery. Fibrocaps is clearly differentiated from existing liquid tissue sealants and hemostats: it is ready for immediate use, is stable at room temperature, and has shown to be safe and efficacious...

Tyrogenex

Tyrogenex is developing X-82, as a targeted therapeutic for ophthalmological diseases and solid tumors. Preliminary data from a phase 1/2 pilot study show that X-82 is well tolerated and did not exhibit any dose-limiting toxicity during the study.

Richmond Pharmacology Ltd

Our goal is to deliver full service Early Phase clinical solutions swiftly, efficiently, and to the highest clinical standard. Our integrated set-up is designed to manage your Early Phase study within the controlled environment of Phase I. We compliment this through our out-patient facilities offering flexibility through the Phases in clinical trials.“Richmond Pharmacology is the UK's only Early...

The Finnish Breast Cancer Group

The study, led by the Finnish Breast Cancer Group, was a large open-label, two-arm, randomised multicentre phase III study in women with early breast cancer. 1,500 patients in Finland and Sweden with no distant metastases who had an intermediate to high risk of recurrence within five years from the time of diagnosis, were recruited to the study.

BioPharma Services, Inc.

BioPharma Services Inc. is a Full-Service Contract Research Organization (CRO) specializing in the conduct of Phase I/IIa clinical trials as well as Bioequivalence trials for international pharmaceutical companies worldwide. The company has clinical facilities both in the U.S.A. and in Canada with a total bed capacity of 250 with access to healthy voluntee...

Opsona Therapeutics Ltd

Opsona is a leading immunology drug development company, focused on novel therapeutic approaches to key targets of the innate immune system associated with a wide range of major human diseases, including autoimmune and inflammatory diseases, transplant rejection, cancer, diabetes, Alzheimer's disease and atherosclerosis. The company was founded in 2004 ...

Annexon Biosciences

Annexon’s pipeline of novel therapies includes two clinical-stage product candidates, ANX005, a monoclonal antibody, and ANX007, a fragmented monoclonal antibody, as well as other compounds in preclinical development. ANX005 is currently in a Phase 1/2 study in patients with Guillain-Barre Syndrome (GBS). Annexon also plans to evaluate ANX005 in complement-mediated neurodegenerative disorder...

NPS Pharmaceuticals, Inc.

NPS Pharmaceuticals is developing new treatment options for patients with rare gastrointestinal and endocrine disorders. The company is currently advancing two Phase 3 registration programs. Teduglutide, a proprietary analog of GLP-2, is being evaluated as GATTEX® in a Phase 3 registration study known as STEPS for intestinal failure associated with shor...

Genosco

Located in Cambridge, MA, Genosco is a clinical-stage biotechnology company led by CEO, Dr. Jong Sung (John) Koh, focusing on developing and commercializing novel immunology and oncology treatments to improve the lives of patients. Genosco’s core competence comes from its expertise in generating selective kinase inhibitors that include candidates that ...


More From BioPortfolio on "A Phase 1 Study in Healthy Volunteers for AL101"

Quick Search

Corporate Database Quicklinks